InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens First-Ever Pneusomnia Clinic, Unveils New Tech to Test for Sleep Apnea at Home
March 8, 2021

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens First-Ever Pneusomnia Clinic, Unveils New Tech to Test for Sleep Apnea at Home

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has opened the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center. The center will feature the Vivos System through its Medical Integration Division. Located in Del Mar, California, the clinic is owned and operated by local physicians, including Dr. Mimi Guarneri, a cardiologist, founder and president of the Academy of Integrative Health and Medicine; she will lead the center. Vivos created its Medical Integration Division last year with the objective of fostering an environment where medical doctors and dentists could work together in treating sleep disorders. The new sleep medicine center will offer the Vivos System, a clinically effective, nonsurgical, noninvasive, nonpharmaceutical oral appliance treatment for mild-to-moderate sleep apnea. In addition to the opening of the new center, Vivos recently launched a new testing technology called VivoScore(TM), powered by SleepImage(R). According to the announcement, VivoScore is a home sleep apnea test (“HSAT”) that builds upon proprietary cardiopulmonary coupling technology developed by SleepImage, or MyCardio LLC, which has been FDA cleared for the purpose of diagnosing OSA. The device includes a single-sensor ring recorder that connects with a smartphone app and uses proprietary cloud-based algorithms to evaluate sleep quality and clinically diagnose sleep apnea in a person’s own home. Studies indicate that VivoScore test results are comparable to overnight in-lab polysomnogram (“PSG”) tests. VivoScore can be used for both children and adults, and is designed to increase access and decrease costs of other HSAT options. “With the medical and dental communities coming together through the Pneusomnia clinics to both diagnose and treat OSA, patients will have access to the Vivos System, our leading-edge technology that helps to alter the size, shape and position of their upper airway tissues,” said Vivos CEO Kirk Huntsman in one of the press releases. “We look forward to continuing our work with Dr. Guarneri to bring as many patients into the new facility as possible. With additional centers opening later this year across the country, and over 1,200 independent dentists in the U.S. and Canada who are now using the Vivos System, we believe we are poised to reach even more undiagnosed patients than ever before.”

To view the full press releases, visit https://ibn.fm/jZsj0 and https://ibn.fm/TPuFj

About Vivos Therapeutics  Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in more than 18,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.  

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).